rejuvant life tabs

Alkahest announces phase 2 study treatment of cognitive impairment

Latest articles

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...

New research institute focuses on science of aging

New Bakar Aging Research Institute aims to drive deeply collaborative research to enhance translational medicine, progressing novel therapies from lab to clinic to community. UC...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...
Rejuvant

Extra-corporeal medical device could improve neuro outlook for end-stage renal disease patients.

Alkahest has announced its first foray into dialysis-associated dementia with a new randomised, double-blind, feasibility and tolerability study of an extracorporeal medical device.

Longevity.Technology: Using dialysis is a logical next step and a natural complement to their existing portfolio, and the extracorporeal device could prove to be an effective way to mitigate the problems of cognitive decline in a patient population whose renal health is already in critical condition.

The device, called AKST1210, is connected in series extracorporeally with a standard haemodialysis circuit. AKST1210 removes a protein called Beta-2 microglobulin (B2M) from the blood; B2M is a harmful inflammatory immune-associated protein that has been demonstrated to impair cognition in animals. It is thought that it may contribute to cognitive decline and other conditions in patients undergoing haemodialysis for end stage renal disease (ESRD).

We are interested by this device-based direction that Alkahest’s research is taking, which further cements their position at the forefront of biopharmaceutical research into neurodegenerative and age-related diseases. The Alkahest pipeline includes multiple therapeutic candidates, including selected plasma fractions, protein-targeted interventions and plasma-based therapies.

AKST1210 has emerged from stealth and is heading to Phase 2 (Source: Alkahest.com)

Elevant

B2M has also been identified by Alkahest as a protein in the blood that increases as we age; success in this trial could indicate B2M as a target for aging research.

The number of patients on dialysis was 2.62 million in 2010 [1]. These patients are at a high risk of cognitive impairment, which is thought to be caused by the harmful accumulation of plasma proteins, such as B2M, in the blood due to an unfortunate by-product of critical blood filtration.

“A large proportion of individuals with end-stage renal disease who receive hemodialysis have cognitive impairment, which may be associated with reduced ability for self-care, poor adherence to dietary and fluid restrictions, and poor outcomes,” said Karoly Nikolich, PhD, chief executive officer of Alkahest.

Elevant

“Alkahest’s preclinical research has demonstrated that Beta-2 microglobulin, which is present at higher levels in older individuals, is drastically elevated in patients undergoing dialysis and may contribute to the high prevalence of cognitive impairment in these individuals. By reducing the amount of B2M in the plasma, we hope to introduce an effective way to lessen this impairment and allow patients on hemodialysis for ESRD to achieve improved treatment outcomes and quality of life [2].”

[1] https://kdigo.org/wp-content/uploads/2017/02/Jha_KDIGO-Dialysis-Jan-2018.pdf
[2] https://bit.ly/3eFAE5h

Images courtesy of Alkahest
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...

Targeting mitochondria to beat hair loss and skin wrinkles

Yuva Biosciences gears up for human trials of cosmeceutical treatments that target mitochondrial dysfunction. With an initial focus on developing cosmeceuticals, US start-up Yuva Biosciences...

HitGen and BioAge progress drug discovery collaboration

Companies announce research progress in DNA-encoded library-based drug discovery research collaboration. Shanghai Stock Exchange-listed biotech HitGen, Inc announced important research progress in a collaboration with...

Renal fibrosis caused by telomere shortening – new research

CNIO researchers demonstrate that renal fibrosis is caused by telomere shortening, paving the way for future treatment. Researchers in the Telomeres and Telomerase Group at...

Nerve regeneration tech targets Alzheimer’s and Nasdaq

NervGen readies for NASDAQ listing and clinical trials of lead compound for nerve regeneration in 2021. With a unique nerve regeneration technology, Canadian biotech NervGen...
Supps report ad middle